Concord Biotech Future Growth
Future criteria checks 5/6
Concord Biotech is forecast to grow earnings and revenue by 22.6% and 18.5% per annum respectively. EPS is expected to grow by 22.6% per annum. Return on equity is forecast to be 22.2% in 3 years.
Key information
22.6%
Earnings growth rate
22.56%
EPS growth rate
| Pharmaceuticals earnings growth | 15.2% |
| Revenue growth rate | 18.5% |
| Future return on equity | 22.25% |
| Analyst coverage | Good |
| Last updated | 15 Oct 2025 |
Recent future growth updates
Concord Biotech Limited (NSE:CONCORDBIO) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 02
Earnings Miss: Here's What Concord Biotech Limited (NSE:CONCORDBIO) Analysts Are Forecasting For Next Year
Feb 16Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14Recent updates
With EPS Growth And More, Concord Biotech (NSE:CONCORDBIO) Makes An Interesting Case
Jul 15Market Participants Recognise Concord Biotech Limited's (NSE:CONCORDBIO) Earnings Pushing Shares 30% Higher
Jun 10Concord Biotech Limited (NSE:CONCORDBIO) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 02Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Apr 08What You Can Learn From Concord Biotech Limited's (NSE:CONCORDBIO) P/E After Its 27% Share Price Crash
Mar 01
Launching New Niche APIs And Commercializing Injectable Plant Will Ensure Future Success
Expansion in formulation business and niche APIs could bolster market share, particularly in oncology and anti-infectives, enhancing revenue and earnings.Earnings Miss: Here's What Concord Biotech Limited (NSE:CONCORDBIO) Analysts Are Forecasting For Next Year
Feb 16Here's Why We Think Concord Biotech (NSE:CONCORDBIO) Might Deserve Your Attention Today
Jan 06Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 20,575 | 6,546 | 5,182 | N/A | 5 |
| 3/31/2027 | 17,016 | 5,239 | 4,267 | N/A | 6 |
| 3/31/2026 | 14,015 | 4,101 | 3,813 | N/A | 6 |
| 6/30/2025 | 11,883 | 3,561 | N/A | N/A | N/A |
| 3/31/2025 | 12,001 | 3,716 | 1,333 | 2,445 | N/A |
| 12/31/2024 | 10,892 | 3,263 | N/A | N/A | N/A |
| 9/30/2024 | 10,857 | 3,279 | 1,939 | 2,995 | N/A |
| 6/30/2024 | 10,379 | 3,132 | N/A | N/A | N/A |
| 3/31/2024 | 10,169 | 3,081 | 1,798 | 2,655 | N/A |
| 12/31/2023 | 9,706 | 3,046 | N/A | N/A | N/A |
| 9/30/2023 | 9,704 | 3,044 | 1,589 | 2,665 | N/A |
| 6/30/2023 | 8,670 | 2,453 | N/A | N/A | N/A |
| 3/31/2023 | 8,532 | 2,401 | 1,009 | 2,460 | N/A |
| 3/31/2022 | 7,129 | 1,749 | 526 | 2,081 | N/A |
| 3/31/2021 | 6,169 | 2,349 | -374 | 1,668 | N/A |
| 3/31/2020 | 5,123 | 1,691 | -6 | 1,548 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CONCORDBIO's forecast earnings growth (22.6% per year) is above the savings rate (6.8%).
Earnings vs Market: CONCORDBIO's earnings (22.6% per year) are forecast to grow faster than the Indian market (16% per year).
High Growth Earnings: CONCORDBIO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CONCORDBIO's revenue (18.5% per year) is forecast to grow faster than the Indian market (10.3% per year).
High Growth Revenue: CONCORDBIO's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CONCORDBIO's Return on Equity is forecast to be high in 3 years time (22.2%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/18 19:51 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Concord Biotech Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |